Alzheimer's, Dementia & Mental Health
Award-Winning Research Points Toward Targeted Alzheimer’s Vaccine
Oral vaccine targets RAGE and amyloid by using body's immune system
|
An accomplice to the
protein that causes plaque buildup in Alzheimer’s disease is the focus of a potential new treatment byh Scott Webster. Phil Jones,
Georgia Health Sciences University photographer |
Sept. 26, 2011 – An accomplice to the protein that causes plaque buildup in Alzheimer's disease is the focus of a
potential new treatment, according to research by a Georgia Health Sciences University graduate student.
In Alzheimer's, the amyloid protein can accumulate in the brain instead of being eliminated by the body's natural
defenses, nestling between the neurons and forming impassable plaques.
Amyloid and the way it gets there could be targets for a new vaccine.
"RAGE, or receptor for advanced glycation endproducts, proteins bind to amyloid and transport it into the brain," said
Scott Webster, a fifth-year graduate student who is studying the disease in the lab of Dr. Alvin Terry, Professor of Pharmacology and
Toxicology. Research has shown that RAGE may also contribute to the inflammation and damage that amyloid causes to the brain's nerve cells.
Webster is researching a vaccine that targets RAGE and amyloid by using the body's own immune system to protect against
their over-production and eventual build-up. His work has earned him the 2011 Darrell W. Brann Scholarship in Neuroscience, a $1,000 award
honoring an outstanding graduate student on the Augusta, Ga. campus working in neuroscience.
"Unfortunately, all of the vaccines for Alzheimer's that have been through clinical trials have failed," he said. "Part
of the reason why could be that they're just not comprehensive enough. Most only target amyloid. Our hope is that by taking a more
encompassing approach, we will be more effective. So far, that's exactly what we're seeing in our experiments."
Other vaccines also have multiple side effects, including swelling of the brain. Webster hopes that targeting the RAGE
protein and changing how the vaccine is administered will minimize inflammatory side effects.
Another benefit is that the vaccine can be administered orally, since it does not require an adjuvant, which is added to
vaccines to enhance the immune response. The digestive tract is one of the body's largest repositories of human flora, microorganisms that are
key to the immune system.
"That's a relatively new idea," Webster said. "By using the immune system that's endogenous to our gut, we can skew the
body's response away from the inflammatory and toward a more robust antibody response, bypassing some of the side effects."
Early results have shown improved cognition and memory in animal models of Alzheimer's, something Webster considers a
sort of personal crusade.
"I have watched a close family friend suffer from the disease and saw how devastating it was," he said. "The family is
caring for this person and yet the person doesn't even remember who his own family is. It's a heartbreaking process to watch."
Even with promising results, he cautioned of unknowns about the potential vaccine.
"We need to move on to larger animal studies. We have a lot we still don't know about the vaccine itself. For example, we
know that amyloid and RAGE bind together, but we don't know why the binding creates such a stable complex. We have these end points, but we
still don't know some of the basic science that needs to be known so that we can push ahead."
In addition to the Brann Scholarship, Webster's research has earned him an invitation to the St. Jude National Graduate
Student Symposium and the National Institutes of Health National Graduate Student Research Conference. He is also a two-time recipient of the
Lowell Greenbaum Award for Research Excellence in Pharmacology.
